January 20, 2022
In a new article, researchers from the Center for Prostate Disease Research, a research center of the Uniformed Services University of the Health Sciences and administered by HJF under a Cooperative agreement, developed a drug to treat a common type of prostate cancer that affects 50-65% of men. The article was published in the American Chemical Society Medicinal Chemistry Letters on October 19, 2021. The article was co-authored by multiple HJF teammates including the lead author Binil Eldhose.
“Prostate cancer is among the leading causes of cancer-related death of men in the United States,” said Eldhose. “The erythroblast transformation-specific gene, or ERG, can fuse with other genes to form a cancer-causing gene mutation and complicate prostate disease treatments. This can contribute to the progression of prostate cancer. In collaboration with the Oregon Health and Science University, we developed a new potent ERG inhibitor which can selectively target ERG harboring prostate cancer.